- Home
- STKS vs TCRX Comparison
STKS vs TCRX Comparison
Compare STKS & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STKS
- TCRX
- Stock Information
- Founded
- STKS 2004
- TCRX 2018
- Country
- STKS United States
- TCRX United States
- Employees
- STKS N/A
- TCRX N/A
- Industry
- STKS Restaurants
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- STKS Consumer Discretionary
- TCRX Health Care
- Exchange
- STKS Nasdaq
- TCRX Nasdaq
- Market Cap
- STKS 112.2M
- TCRX 100.7M
- IPO Year
- STKS N/A
- TCRX 2021
- Fundamental
- Price
- STKS $3.43
- TCRX $1.44
- Analyst Decision
- STKS Buy
- TCRX Strong Buy
- Analyst Count
- STKS 2
- TCRX 6
- Target Price
- STKS $4.25
- TCRX $9.50
- AVG Volume (30 Days)
- STKS 58.7K
- TCRX 470.2K
- Earning Date
- STKS 08-05-2025
- TCRX 08-11-2025
- Dividend Yield
- STKS N/A
- TCRX N/A
- EPS Growth
- STKS N/A
- TCRX N/A
- EPS
- STKS N/A
- TCRX N/A
- Revenue
- STKS $799,478,000.00
- TCRX $4,421,000.00
- Revenue This Year
- STKS $28.67
- TCRX $159.20
- Revenue Next Year
- STKS $5.12
- TCRX N/A
- P/E Ratio
- STKS N/A
- TCRX N/A
- Revenue Growth
- STKS 138.50
- TCRX N/A
- 52 Week Low
- STKS $2.37
- TCRX $1.02
- 52 Week High
- STKS $5.42
- TCRX $7.89
- Technical
- Relative Strength Index (RSI)
- STKS 46.52
- TCRX 44.26
- Support Level
- STKS $3.35
- TCRX $1.44
- Resistance Level
- STKS $3.80
- TCRX $1.61
- Average True Range (ATR)
- STKS 0.29
- TCRX 0.16
- MACD
- STKS -0.04
- TCRX -0.02
- Stochastic Oscillator
- STKS 34.57
- TCRX 10.44
About STKS The ONE Group Hospitality Inc.
The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through four segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.